Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | LPL | P06858 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26314552 | 0.77 | ENPP2 (0.42) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL38656446 | 0.77 | ENPP2 (0.42) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL25702943 | 0.76 | CA1 (0.33) | ENPP2CA2CA1 | |
| SCHEMBL10092631 | 0.75 | ENPP2 (0.40) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL29547779 | 0.73 | CA2 (0.48) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL113132 | 0.73 | NOS3 (0.44) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL29850392 | 0.73 | ENPP2 (0.48) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL181140 | 0.73 | CA2 (0.48) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL22841181 | 0.73 | ENPP2 (0.39) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL116584 | 0.73 | CA2 (0.48) | ENPP2CA2CA1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119570356-A | Wear-resistant butterfly valve and processing method thereof | 迪力阀门科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| EP-4100394-B1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4660183-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING PHENOLIC COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| US-12492194-B2 | HPK1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-09 | — | — | US | disclosed |
| US-12454529-B2 | Piperazine cyclic ureas | Sironax Ltd. (KY) | 2025-10-28 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| CN-115362145-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4035688-B1 | MRI IMAGING OF AMYLOID PLAQUE USING LIPOSOMES | Texas Childrens Hospital (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| CN-119570356-A | Wear-resistant butterfly valve and processing method thereof | 迪力阀门科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071819-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-2155753-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009105500-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | ENPP2 2205/4885CA2 3399/4885CA1 4800/4885 |
| US-12454529-B2 | Piperazine cyclic ureas | RIPK1, RIPK3, RIPK4 | ENPP2 3013/4885CA2 3090/4885CA1 2940/4885 |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | ENPP2 461/4885CA2 1974/4885CA1 4176/4885 |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | ENPP2 2761/4885CA2 4281/4885CA1 4447/4885 |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | ENPP2 4/4885CA2 2244/4885CA1 3460/4885 |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CASP3 | ENPP2 1637/4885CA2 3729/4885CA1 4346/4885 |
| US-12492194-B2 | HPK1 inhibitors | PGK1, PCK1, PDXK | ENPP2 370/4885CA2 3741/4885CA1 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.